HUTCHMED (China) Limited announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanc...
Andelyn Biosciences, Inc., a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Q...
Announcing expansion of capabilities to provide customers with a broader range of DNA synthesis solutions, allowing IDT to complement and extend ...
Johnson & Johnson announced that the European Commission (EC) has approved an indication extension for TECVAYLI®(teclistamab) in combination with...
New Curitics Point of Care Solution, Ambient Listening, AI Care Management, and mobile capabilities help reduce administrative burden, strengthen care co...
GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to redu...
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces a breakthrough in RF resection technology for hip with its new FLOW FLE...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced to...
HUTCHMED (China) Limited announces that positive high-level results from the SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO®...
-Enigma Biomedical USA (EB USA) today announced the U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection, a...
NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX, OTCQB: NRXBF, FSE: J90), a biotechnology company developing exosome-based regenerative t...
Prescription Drug User Fee Act target action date is February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for Stargar...
PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, announced the upcoming availability of SPRQ-Nx chemistry and...
CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM). Under...
© 2026 Biopharma Boardroom. All Rights Reserved.
